A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma – Results of systematic literature research

IF 7.1 1区医学 Q1 ONCOLOGY European Journal of Cancer Pub Date : 2025-01-17 DOI:10.1016/j.ejca.2024.115160

Teresa Amaral , Lena Nanz , Lina Maria Serna Higuita , Paolo Ascierto , Carola Berking , Eva Muñoz Couselo , Marco Donia , Reinhard Dummer , Ralf Gutzmer , Axel Haushild , Mathilde Jalving , Rebecca Lee , Paul Lorigan , Ivan Marquez-Rodas , Olivier Michelin , Paul Nathan , Caroline Robert , Dirk Schadendorf , Pawel Sobczuk , Lukas Flatz , Claus Garbe

{"title":"A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma – Results of systematic literature research","authors":"Teresa Amaral , Lena Nanz , Lina Maria Serna Higuita , Paolo Ascierto , Carola Berking , Eva Muñoz Couselo , Marco Donia , Reinhard Dummer , Ralf Gutzmer , Axel Haushild , Mathilde Jalving , Rebecca Lee , Paul Lorigan , Ivan Marquez-Rodas , Olivier Michelin , Paul Nathan , Caroline Robert , Dirk Schadendorf , Pawel Sobczuk , Lukas Flatz , Claus Garbe","doi":"10.1016/j.ejca.2024.115160","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies.</div></div><div><h3>Methods</h3><div>We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software.</div></div><div><h3>Results</h3><div>Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival.</div></div><div><h3>Conclusion</h3><div>Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"215 ","pages":"Article 115160"},"PeriodicalIF":7.1000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924017672","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies.

Methods

We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software.

Results

Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival.

Conclusion

Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

BRAF V600突变黑色素瘤III期患者辅助治疗的真实世界数据比较--系统文献研究的结果。

背景：在过去十年中，基于 PD-1 的免疫检查点抑制剂（ICI）以及 BRAF 和 MEK 抑制剂靶向疗法（TT）改变了黑色素瘤的治疗。两者都被广泛用于辅助治疗。然而，对于 BRAF V600 基因突变的患者，由于缺乏头对头比较研究，最佳辅助治疗方法仍不明确：我们对 III 期黑色素瘤辅助治疗的真实数据进行了系统回顾，以确定 BRAF V600 突变患者的最佳选择。使用 Digitizelt 软件生成了 TT 和 ICI 的 Kaplan-Meier 曲线：结果：共收录了9篇文献，3625名患者。TT在6、12、24和36个月的无复发生存期（RFS）均优于ICI。在无远处转移生存期（DMFS）方面也观察到类似的趋势，但总生存期没有明显差异：真实世界的数据表明，与 ICI 相比，TT 辅助治疗 III 期 BRAF V600 突变黑色素瘤可获得更好的复发生存期（RFS）和无远处转移生存期（DMFS）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.